<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01925066</url>
  </required_header>
  <id_info>
    <org_study_id>B-1206-156-004</org_study_id>
    <nct_id>NCT01925066</nct_id>
  </id_info>
  <brief_title>Aerosolized Vancomycin in Methicillin-Resistant Staphylococcus Aureus Pneumonia Under Mechanical Ventilation</brief_title>
  <official_title>Optimal Two-Stage Phase 2 Study of Efficacy and Pharmacokinetics of Aerosolized Vancomycin in Methicillin-Resistant Staphylococcus Aureus Pneumonia Under Mechanical Ventilation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether aerosolized vancomycin is effective in the
      treatment of methicillin-resistant staphylococcus aureus pneumonia under mechanical
      ventilation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical cure rate</measure>
    <time_frame>within the first 30 days after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the peak level of serum vancomycin level</measure>
    <time_frame>on 3rd and 5th days after treatment</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>microbiological response</measure>
    <time_frame>within the first 30 days after treatment</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Pneumonia, Staphylococcal</condition>
  <condition>Methicillin-Resistant Staphylococcus Aureus</condition>
  <arm_group>
    <arm_group_label>Aerosolized Vancomycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <arm_group_label>Aerosolized Vancomycin</arm_group_label>
    <other_name>250mg bid, Inhalation for 5-7 days</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Nosocomial or severe community-acquired pneumonia due to Methicillin-Resistant
             Staphylococcus aureus

          -  Must be mechanically ventilated in intensive care unit

        Exclusion Criteria:

          -  Non-bacterial pneumonia, such as viral, fungal, tuberculosis infections

          -  Underlying respiratory condition: bronchiectasis, post-tuberculosis, chronic
             obstructive pulmonary disease or asthma

          -  Complicated pneumonia, such as empyema, parapneumonic effusion requiring chest tube or
             drainage

          -  Already or previous treated with intravenous vancomycin (Not pneumonia)

          -  Adverse reaction due to inhaled ventolin before treatment of aerosolized vancomycin

          -  Hypersensitivity of vancomycin or glycopeptide antibiotics

          -  Positive culture of Enterococcus in respiratory specimen

          -  Pregnant or Breast-feeding patient

          -  Immunocompromised hosts: more than 1mg/kg of corticosteroid users for more than 3
             months, transplantation recipients, AIDS patients

          -  Another aerosolized antibiotics within 48 hours of study enrollment

          -  Not adherent to mechanical ventilation protocol of this study

          -  Not arterial line monitoring

          -  Vancomycin minimum inhibitory concentration &gt;= 2㎍/㎖ of cultured Staphylococcus aureus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae-Joon Yim, MD</last_name>
    <role>Study Director</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi-do</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://linus.nci.nih.gov/brb/samplesize/otsd.html</url>
    <description>Optimal Two-Stage Designs For Phase II Clinical Trials</description>
  </link>
  <reference>
    <citation>Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989 Mar;10(1):1-10.</citation>
    <PMID>2702835</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>August 15, 2013</study_first_submitted>
  <study_first_submitted_qc>August 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2013</study_first_posted>
  <last_update_submitted>April 21, 2019</last_update_submitted>
  <last_update_submitted_qc>April 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Staphylococcal Infections</mesh_term>
    <mesh_term>Pneumonia, Staphylococcal</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

